BioSig Technologies, Inc. (OTC: BSGM) is a medical device company that is developing a proprietary technology platform designed to improve the rapidly growing $3 billion electrophysiology (EP) marketplace. Led by a proven management team and a veteran, independent Board of Directors, Minneapolis-based BioSig is preparing to commercialize its PURE EP System. PURE EP is designed to improve the clarity of clinical signals available for EP studies and cardiac catheter ablation. It is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system. For more information, visit the company’s website at www.biosigtech.com